Online inquiry

IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3821MR)

This product GTTS-WQ3821MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets NCAM1 gene. The antibody can be applied in Small Cell Lung Cancer (SCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000615.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4684
UniProt ID P13591
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3821MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9756MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JS001
GTTS-WQ3399MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA aALB03
GTTS-WQ334MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 1F5
GTTS-WQ9459MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IPH4102
GTTS-WQ12319MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MT203
GTTS-WQ10210MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LDP-02
GTTS-WQ4279MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BIIB-033
GTTS-WQ14168MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aIL6R88
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW